Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F T Valentine

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1997
Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responsesS K Kundu, D Katzenstein, F T Valentine, et al.
Annals of Internal Medicine|April 1, 1992
Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trialG L Drusano, G J Yuen, J S Lambert, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1974
Effects of dialyzable transfer factor in patients with breast cancerH F Oettgen, L J Old, J H Farrow, et al.
The Journal of Infectious Diseases|January 1, 1994
Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoringM D Hughes, D S Stein, H M Gundacker, et al.
The Journal of Infectious Diseases|June 1, 1984
Acquired immune deficiency syndrome possibly related to transfusion in an adult without known disease-risk factorsS M Gordon, F T Valentine, R S Holzman, et al.
Clinical Pharmacology and Therapeutics|May 1, 1991
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complexC A Knupp, W C Shyu, R Dolin, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trialsG L Drusano, G J Yuen, G Morse, et al.
Annals of Internal Medicine|March 13, 1999
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258R M Gulick, V McAuliffe, J Holden-Wiltse, et al.
The New England Journal of Medicine|May 10, 1990
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trialJ S Lambert, M Seidlin, R C Reichman, et al.
The Journal of Infectious Diseases|June 1, 1996
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|August 1, 1997
Effect of therapeutic immunization with recombinant gp160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: relationship to cellular immune responsesS K Kundu, D Katzenstein, F T Valentine, et al.
Annals of Internal Medicine|April 1, 1992
Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trialG L Drusano, G J Yuen, J S Lambert, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1974
Effects of dialyzable transfer factor in patients with breast cancerH F Oettgen, L J Old, J H Farrow, et al.
The Journal of Infectious Diseases|January 1, 1994
Within-subject variation in CD4 lymphocyte count in asymptomatic human immunodeficiency virus infection: implications for patient monitoringM D Hughes, D S Stein, H M Gundacker, et al.
The Journal of Infectious Diseases|June 1, 1984
Acquired immune deficiency syndrome possibly related to transfusion in an adult without known disease-risk factorsS M Gordon, F T Valentine, R S Holzman, et al.
Clinical Pharmacology and Therapeutics|May 1, 1991
Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complexC A Knupp, W C Shyu, R Dolin, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1992
Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trialsG L Drusano, G J Yuen, G Morse, et al.
Annals of Internal Medicine|March 13, 1999
Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258R M Gulick, V McAuliffe, J Holden-Wiltse, et al.
The New England Journal of Medicine|May 10, 1990
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trialJ S Lambert, M Seidlin, R C Reichman, et al.
The Journal of Infectious Diseases|June 1, 1996
A randomized, placebo-controlled study of the immunogenicity of human immunodeficiency virus (HIV) rgp160 vaccine in HIV-infected subjects with > or = 400/mm3 CD4 T lymphocytes (AIDS Clinical Trials Group Protocol 137)F T Valentine, S Kundu, P A Haslett, et al.
Pageof 4